Patents Assigned to Hopital Maisonneuve-Rosemont
  • Patent number: 8802082
    Abstract: Compositions and methods for reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation are described. A method includes harvesting hematopoietic cells from a patient with an immunologic disorder and harvesting hematopoietic cells from a donor. The harvested hemaptopoietic cells from the patient and the donor are mixed ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from the donor such that an immune reaction occurs and an activated portion and an unactivated portion is produced. A rhodamine B derivative is then added to the mixture of cells and the mixture is irradiated at a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient. The irradiated cells are then infused into the patient.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: August 12, 2014
    Assignees: Universite de Montreal, Hopital Maisonneuve-Rosemont
    Inventors: Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve
  • Publication number: 20130295059
    Abstract: Compositions and methods for reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation are described. A method includes harvesting hematopoietic cells from a patient with an immunologic disorder and harvesting hematopoietic cells from a donor. The harvested hemaptopoietic cells from the patient and the donor are mixed ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from the donor such that an immune reaction occurs and an activated portion and an unactivated portion is produced. A rhodamine B derivative is then added to the mixture of cells and the mixture is irradiated at a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient. The irradiated cells are then infused into the patient.
    Type: Application
    Filed: March 29, 2013
    Publication date: November 7, 2013
    Applicants: HOPITAL MAISONNEUVE-ROSEMONT, UNIVERSITE DE MONTREAL
    Inventors: UNIVERSITE DE MONTREAL, HOPITAL MAISONNEUVE-ROSEMONT
  • Patent number: 8409564
    Abstract: The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: April 2, 2013
    Assignees: Universite de Montreal, Hopital Maisonneuve-Rosemont
    Inventors: Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve
  • Publication number: 20060088507
    Abstract: The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.
    Type: Application
    Filed: October 21, 2004
    Publication date: April 27, 2006
    Applicants: Universite de Montreal, Hopital Maisonneuve-Rosemont
    Inventors: Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve